- Acquisition: Seven2 acquires the company specialized in artificial intelligence ILLUIN Technology.
- Acquisition: IK Partners acquires the insurance brokerage company Ascora Group.
- Acquisition: The pharmaceutical product distributor Swixx BioPharma reorganizes its shareholding.
- Add-on: Aminolabs acquires the dietary supplements manufacturer CeeBe Health & Nutrition.
SEVEN2 PARTNERS
Acquisition: Seven2 acquires the company specialized in artificial intelligence ILLUIN Technology
Seven2 announces the acquisition of a majority stake in ILLUIN Technology (€10.1 million of revenue in 2024, Île-de-France / FRA), a company specializing in artificial intelligence, data engineering, software development, and advanced digital solutions for businesses, providing modular and scalable tools from the latest research and technology advancements. With the support of Seven2, the company aims to accelerate its growth by strengthening its investments in products and R&D and consolidating its position as a leader in AI solutions for large businesses (Seven2, press release)
IK PARTNERS
Acquisition: IK Partners acquires the insurance brokerage company Ascora Group
As part of an MBO, IK Partners, via IK Small Cap IV, acquires a majority stake in Ascora Group (€10.7 million of revenue in 2024, Île-de-France / FRA), an insurance brokerage company supporting businesses, associations, individuals, and real estate players with tailor-made solutions, offering various offers and products covering distribution, underwriting, contract production, and claims management. Following this transaction, Ascora intends to continue its consolidation strategy through targeted acquisitions (IK Partners, press release)
SK CAPITAL PARTNERS
Acquisition: The pharmaceutical product distributor Swixx BioPharma reorganizes its shareholding
SK Capital Partners announces the acquisition of Swixx BioPharma (c. CHF 839.1 million of revenue in 2023, Central Switzerland / CHE), a company specializing in the commercialization and distribution of innovative pharmaceutical products and health solutions on behalf of international laboratories in markets where they do not have a direct presence. As part of this transaction, the founders and the management will retain significant stakes, while the existing investors, Mérieux Equity Partners, present in the capital since 2021, and HBM Healthcare Investments, a shareholder since 2017, will remain committed shareholders. Swixx BioPharma will continue to position itself as a major pharmaceutical commercialization platform, active in 45 countries, with expected revenue of €1.3 billion in 2026 (SK Capital Partners, press release)
LRM MANAGEMENT
Add-on: Aminolabs acquires the dietary supplements manufacturer CeeBe Health & Nutrition
Owned by LRM Management, Aminolabs (Flemish Region / BEL) is a company that produces and distributes dietary and nutritional supplements in the form of packaged powders, sachets, liquids, gels, capsules, and tablets, acquires CeeBe Health & Nutrition (Flemish Region / BEL), a company specialized in the development and manufacturing of private label dietary supplements, offered in various forms, including effervescent tablets, capsules, powders, and gummies. This operation allows Aminolabs to expand its expertise and strengthen its support for brands of all sizes, while CeeBe will benefit from the purchasing power, enhanced R&D capabilities, and the wide range of production solutions of Aminolabs (LRM Management, press release)
